Observational Study of the Use of Extraneal in Peritoneal Dialysis in Patients

Patients will be divided into icodextrin dialysate group (ICO group) and glucose dialysate group (glucose group).

ICO group: Patient data will be collected retrospectively and prospectively. Patients currently prescribed icodextrin will be recruited and enrolled. Data for these patients will included both retrospective historical data collection as well as a prospective collection of additional data. Within the relative look-back period (i.e., within 6 months before the launch of the study site), data will be collected from baseline (i.e., the most recent medical records prior to the first prescription of icodextrin) up to signing of the ICF. After providing informed consent, patient data will be prospectively collected for 12 months.

Additionally, any patients who are first prescribed icodextrin therapy after the launch of the study site will also be recruited and enrolled prospectively and data will be collected up to 12 months from enrollment for this group. For these patients, baseline will be defined as the most recent medical record from the time of signing the ICF to the first prescription of icodextrin.

Glucose group: Patient data will be collected retrospectively from CAPD patients followed up in the peritoneal dialysis center from July 1, 2018, to December 31, 2018. Retrospective data will be collected up to 12 months from baseline (i.e., the most recent peritoneal equilibration test date before December 31, 2018, in the peritoneal dialysis center).

The effectiveness and safety between the 2 groups will be analyzed.

Inclusion criteria

for patients enrolled retrospectively in the ICO Group:

• Age ≥ 18 years old at first prescription of icodextrin, male or female;
• With a definite diagnosis of CRF and on maintenance PD ≥ 3 months;
• On CAPD treatment;
• Being treated with icodextrin long dwell exchange with an icodextrin prescription ≤ 6 months with essential baseline information(including age, gender, PD vintage, presence of diabetes or not, PET, and assessment of dialysis adequacy);
• Voluntarily sign the informed consent form (ICF) and be willing to complete the study visits as required by the investigator (For death cases, exemption of the informed consent will be applied with approval of the ethics committee).

Inclusion criteria

for patients enrolled prospectively in the ICO Group:

• Age ≥ 18 years old, male or female;
• Patients with a definite diagnosis of CRF and on maintenance PD ≥ 3 months;
• On CAPD treatment, with planned prescription for icodextrin;
• Voluntarily sign the ICF and be willing to complete the study visits as required by the investigator.

Exclusion criteria

for the ICO Group:

• Those with combined HD within 30 days prior to enrolment;
• History of peritonitis within 30 days prior to enrolment or presence of acute or chronic exit site infection or tunnel infection at enrolment;
• Participation in another interventional study within 30 days prior to enrolment or concurrently with this study;
• Allergy to any components of Icodextrin;
• Pregnancy or in lactation;
• Any other condition for which the investigator considers the patient to be unsuitable for participation in this study.

Inclusion criteria

for the Glucose Group:

• Age ≥ 18 years at baseline, male or female;
• Those with a definitive diagnosis of CRF prior to baseline and eligible for CAPD treatment with Baxter's glucose PD solutions between July 1, 2018 and December 31, 2018;
• On maintenance PD ≥ 3 months;
• Essential baseline information (including age, gender, PD vintage, presence of diabetes or not, peritoneal transport status, dialysis adequacy assessment, 24-hour urine volume);
• Any prescription of Baxter's glucose PD solutions and medical records of clinical events within 1 year from baseline.

Exclusion criteria

for the Glucose Group:

• Those with combined HD within 30 days prior to baseline;
• History of peritonitis within 30 days prior to baseline or presence of acute or chronic exit site infection or tunnel infection during baseline;
• Prescription of non-Baxter PD solutions within 1 month prior to baseline.
• Patients enrolled in the ICO group.